01—Abstract
Summary
Summary of the 8-K filed October 2, 2024. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc. (MRNA) announced a change to its Board of Directors through an 8-K filing on October 2, 2024.
The key development is the appointment of Abbas Hussain as a new director, effective October 2, 2024. Mr. Hussain brings significant experience in the healthcare sector, having previously served as CEO of Vifor Pharma and holding various leadership roles at GlaxoSmithKline and Eli Lilly and Company. His appointment increases the Board size to nine directors, and he will serve as a Class II director until the 2026 annual meeting.
Furthermore, Mr. Hussain has been appointed to the Board's Audit Committee. This addition to the Board signifies a strengthening of Moderna's governance and oversight, particularly within its audit functions, by leveraging Mr. Hussain's extensive industry leadership and operational background.
Investors should note that his compensation will align with the company's established non-employee director compensation policy, and he has entered into standard indemnification agreements. There are no disclosed related-party transactions or disqualifying arrangements associated with his appointment.
02—Key points
Key Highlights
- Abbas Hussain appointed to Moderna's Board of Directors, effective October 2, 2024.
- Mr. Hussain brings extensive healthcare leadership experience, including as former CEO of Vifor Pharma and prior roles at GlaxoSmithKline and Eli Lilly.
- The Board size has been increased to nine directors to accommodate the new appointment.
- Mr. Hussain will serve as a Class II director with a term extending to the 2026 annual meeting.
- He has been appointed to serve on the Board's Audit Committee, strengthening financial oversight.
- Compensation for Mr. Hussain will follow Moderna's standard non-employee director compensation policy.
- No related-party transactions or disqualifying arrangements were disclosed for Mr. Hussain's appointment.
03—Questions
Frequently Asked Questions
What is the significance of Abbas Hussain's appointment to Moderna's Board?
Abbas Hussain's appointment is significant as he brings decades of leadership and operating experience from the healthcare industry, including his most recent role as CEO of Vifor Pharma. His appointment, particularly to the Audit Committee, is expected to enhance the Board's expertise in financial oversight and strategic decision-making within the pharmaceutical and biotechnology sector.
How does this appointment affect the size and composition of the Board?
Mr. Hussain's appointment has increased the size of Moderna's Board of Directors from eight to nine members. He has been designated as a Class II director, meaning his term will run until the 2026 annual meeting of shareholders, providing continuity and a fresh perspective to the Board's ongoing governance.
What are the financial implications for Mr. Hussain's role as a director?
Mr. Hussain will be compensated in accordance with Moderna's established Non-Employee Director Compensation Policy. This includes an initial grant and a pro-rata portion of an annual grant, as detailed in the company's proxy statement. These arrangements are standard for non-employee directors and do not indicate any special compensation packages outside of the policy.
Are there any potential conflicts of interest or related-party transactions involving Mr. Hussain?
Based on the filing, there are no disclosed arrangements or understandings between Mr. Hussain and any other person that led to his appointment. Furthermore, there are no reported family relationships with current directors or officers, and no transactions or relationships reportable under Item 404(a) of Regulation S-K, suggesting no immediate conflicts of interest were identified by the company.
04—Continue